ADMA Biologics Inc (ADMA)vsRevolution Medicines Inc (RVMD)
ADMA
ADMA Biologics Inc
$13.19
+0.38%
HEALTHCARE · Cap: $2.93B
RVMD
Revolution Medicines Inc
$176.35
-2.41%
HEALTHCARE · Cap: $41.76B
Smart Verdict
WallStSmart Research — data-driven comparison
ADMA Biologics Inc generates 163% more annual revenue ($519.15M vs $197.56M). ADMA leads profitability with a 35.1% profit margin vs 0.0%. ADMA earns a higher WallStSmart Score of 64/100 (C+).
ADMA
Buy64
out of 100
Grade: C+
RVMD
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+89.8%
Fair Value
$1883.88
Current Price
$176.35
$1707.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Earnings expanding 46.7% YoY
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 44.9%.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ADMA
No major red flags identified for ADMA, but monitor valuation.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ADMA profiles as a mature stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.43 — expect wider price swings.
ADMA is growing revenue faster at 5.1% — sustainability is the question.
ADMA generates stronger free cash flow (15M), providing more financial flexibility.
Bottom Line
ADMA scores higher overall (64/100 vs 23/100), backed by strong 35.1% margins. RVMD offers better value entry with a 89.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?